Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Islatravir in Severe Renal Impairment
NCT04303156Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of islatravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Curve From Time 0 to Infinity of Plasma Islatravir at 168 hours, Area Under the Curve From Time 0 to Last Sampling Time of Plasma Islatravir and 5 more. Started Jun 2020; status: completed.
02
Drugs
islatravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04303156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04303156.